Valneva SE (VALN) Non-Current Deffered Revenue (2022)
Valneva SE (VALN) posted Non-Current Deffered Revenue of $499908.4 for Q1 2026, down 0.59% sequentially from $502866.8 in Q4 2025, and down 87.33% YoY from $3.9 million in Q1 2025.
Analysis
Valneva SE (VALN) Non-Current Deffered Revenue (2022) Analysis & Trends
Valneva SE has reported Non-Current Deffered Revenue for 6 years, with the latest figure at $499908.4 in Q1 2026.
- Quarterly Non-Current Deffered Revenue fell 87.33% year-over-year to $499908.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $499908.4 (down 87.33% YoY) and the FY2025 annual result came in at $502866.8, down 84.56% from the prior year.
- Non-Current Deffered Revenue eased to $499908.4 in Q1 2026 per VALN's latest filing, from $502866.8 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $137.5 million in Q1 2022 and troughed at -$5.3 million in Q4 2022.
- A 5-year average of $19.5 million and a median of $5.7 million in 2024 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2022 and 2023: Non-Current Deffered Revenue tumbled 198.59% in 2022, then soared 214.63% in 2023.
- Over 5 years, Non-Current Deffered Revenue stood at -$5.3 million in 2022, then soared by 214.63% to $6.1 million in 2023, then slumped by 47.53% to $3.2 million in 2024, then tumbled by 84.37% to $502866.8 in 2025, then dropped by 0.59% to $499908.4 in 2026.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $499908.4, $502866.8, and $494510.3 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Valneva SE | 580.64 Mn | 439.38 Mn | 1.86 Mn | - |